View Past PerformanceBioSmartLtd バランスシートの健全性財務の健全性 基準チェック /66BioSmartLtdの総株主資本は₩187.7B 、総負債は₩71.8Bで、負債比率は38.3%となります。総資産と総負債はそれぞれ₩309.9Bと₩122.2Bです。 BioSmartLtdの EBIT は₩22.7Bで、利息カバレッジ比率10.7です。現金および短期投資は₩39.1Bです。主要情報38.26%負債資本比率₩71.80b負債インタレスト・カバレッジ・レシオ10.7x現金₩39.11bエクイティ₩187.66b負債合計₩122.22b総資産₩309.88b財務の健全性に関する最新情報分析記事 • Apr 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Aug 01BioSmartLtd (KOSDAQ:038460) Seems To Be Using A Lot Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • May 02Here's Why BioSmartLtd (KOSDAQ:038460) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Mar 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Nov 29These 4 Measures Indicate That BioSmartLtd (KOSDAQ:038460) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • May 11Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩3,735, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 11x in the Tech industry in South Korea. Total returns to shareholders of 17% over the past three years.お知らせ • Mar 13BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,360, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total returns to shareholders of 20% over the past three years.分析記事 • Feb 02What BioSmart Co.,Ltd.'s (KOSDAQ:038460) 44% Share Price Gain Is Not Telling YouBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have continued their recent momentum with a 44% gain in the last month...New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩143.6b market cap, or US$99.1m).Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩5,680, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 50% over the past three years.分析記事 • Dec 15BioSmart Co.,Ltd.'s (KOSDAQ:038460) Shares Climb 44% But Its Business Is Yet to Catch UpBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have had a really impressive month, gaining 44% after a shaky period...New Risk • Dec 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩100.3b market cap, or US$68.5m).Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩3,970, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 11x in the Tech industry in South Korea. Total returns to shareholders of 8.2% over the past three years.New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩74.9b market cap, or US$54.0m).分析記事 • Apr 23The Market Lifts BioSmart Co.,Ltd. (KOSDAQ:038460) Shares 33% But It Can Do MoreBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders have had their patience rewarded with a 33% share price jump in the...New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.03% net profit margin). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩102.7b market cap, or US$72.2m).分析記事 • Apr 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩6.00 (vs ₩915 in FY 2023)Full year 2024 results: EPS: ₩6.00 (down from ₩915 in FY 2023). Revenue: ₩484.3b (up 6.2% from FY 2023). Net income: ₩127.2m (down 99% from FY 2023). Profit margin: 0% (down from 3.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • Mar 12BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South KoreaNew Risk • Dec 08New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (₩74.2b market cap, or US$52.1m).分析記事 • Nov 13BioSmart Co.,Ltd. (KOSDAQ:038460) May Have Run Too Fast Too Soon With Recent 25% Price PlummetThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has fared very poorly over the last month, falling by a substantial...分析記事 • Oct 14Here's Why We Think BioSmartLtd (KOSDAQ:038460) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩4,205, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩3,810, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 42% over the past three years.分析記事 • Aug 01BioSmartLtd (KOSDAQ:038460) Seems To Be Using A Lot Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jun 15BioSmart Co.,Ltd. (KOSDAQ:038460) Might Not Be As Mispriced As It Looks After Plunging 26%The BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has softened a substantial 26% over the previous 30 days, handing...Valuation Update With 7 Day Price Move • Jun 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,530, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 15x in the Tech industry in South Korea. Total loss to shareholders of 32% over the past three years.お知らせ • Jun 06An unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billionAn unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billion on June 4, 2024. The transaction is expected to close on June 5, 2024.Valuation Update With 7 Day Price Move • May 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩6,560, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 6.0% over the past three years.分析記事 • May 02Here's Why BioSmartLtd (KOSDAQ:038460) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,505, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 11x in the Tech industry in South Korea. Total loss to shareholders of 35% over the past three years.分析記事 • Apr 11Further Upside For BioSmart Co.,Ltd. (KOSDAQ:038460) Shares Could Introduce Price Risks After 52% BounceThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has done very well over the last month, posting an excellent gain...New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Market cap is less than US$100m (₩109.1b market cap, or US$79.8m).Valuation Update With 7 Day Price Move • Apr 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩4,090, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 31% over the past three years.分析記事 • Mar 26Shareholders In BioSmartLtd (KOSDAQ:038460) Should Look Beyond Earnings For The Full StoryWe didn't see BioSmart Co.,Ltd.'s ( KOSDAQ:038460 ) stock surge when it reported robust earnings recently. We looked...Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩915 (vs ₩38.00 in FY 2022)Full year 2023 results: EPS: ₩915 (up from ₩38.00 in FY 2022). Revenue: ₩456.2b (up 16% from FY 2022). Net income: ₩17.9b (up ₩17.2b from FY 2022). Profit margin: 3.9% (up from 0.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jan 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to ₩3,370. The fair value is estimated to be ₩2,795, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 87%.Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩3,720, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 65% over the past three years.New Risk • Oct 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (₩72.0b market cap, or US$53.6m).New Risk • Sep 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (₩71.8b market cap, or US$54.2m).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩3,070, the stock trades at a trailing P/E ratio of 54.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 34% over the past three years.Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩4,515, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 9.1% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩3,905, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 10x in the Tech industry in South Korea. Total loss to shareholders of 14% over the past three years.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • Mar 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Mar 04New 90-day low: ₩6,140The company is down 19% from its price of ₩7,600 on 04 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 20% over the same period.分析記事 • Feb 16Returns On Capital At BioSmartLtd (KOSDAQ:038460) Paint An Interesting PictureThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...分析記事 • Jan 29Declining Stock and Decent Financials: Is The Market Wrong About BioSmart Co.,Ltd. (KOSDAQ:038460)?It is hard to get excited after looking at BioSmartLtd's (KOSDAQ:038460) recent performance, when its stock has...Is New 90 Day High Low • Jan 29New 90-day low: ₩6,230The company is down 37% from its price of ₩9,920 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 48% over the same period.分析記事 • Jan 11BioSmartLtd (KOSDAQ:038460) Shareholders Have Enjoyed A 51% Share Price GainBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders might be concerned after seeing the share price drop 26% in the last...Is New 90 Day High Low • Jan 08New 90-day low: ₩7,280The company is down 28% from its price of ₩10,100 on 08 October 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 39% over the same period.分析記事 • Dec 23BioSmart Co.,Ltd. (KOSDAQ:038460) Looks Interesting, And It's About To Pay A DividendBioSmart Co.,Ltd. ( KOSDAQ:038460 ) is about to trade ex-dividend in the next four days. Ex-dividend means that...Upcoming Dividend • Dec 22Upcoming Dividend of ₩63.00 Per ShareWill be paid on the 7th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.7% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (1.9%).分析記事 • Dec 17Does BioSmart Co.,Ltd. (KOSDAQ:038460) Have A Place In Your Dividend Portfolio?Dividend paying stocks like BioSmart Co.,Ltd. ( KOSDAQ:038460 ) tend to be popular with investors, and for good reason...Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩9,670, the stock is trading at a trailing P/E ratio of 58.2x, up from the previous P/E ratio of 45x. This compares to an average P/E of 24x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 110%.分析記事 • Nov 29These 4 Measures Indicate That BioSmartLtd (KOSDAQ:038460) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Is New 90 Day High Low • Nov 25New 90-day low: ₩8,150The company is down 36% from its price of ₩12,800 on 27 August 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 22% over the same period.Valuation Update With 7 Day Price Move • Nov 09Market bids up stock over the past weekAfter last week's 20% share price gain to ₩11,650, the stock is trading at a trailing P/E ratio of 11.6x, up from the previous P/E ratio of 9.6x. This compares to an average P/E of 16x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 131%.Valuation Update With 7 Day Price Move • Oct 27Market bids up stock over the past weekAfter last week's 19% share price gain to ₩10,750, the stock is trading at a trailing P/E ratio of 10.7x, up from the previous P/E ratio of 8.9x. This compares to an average P/E of 20x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 118%.財務状況分析短期負債: A038460の 短期資産 ( ₩154.2B ) が 短期負債 ( ₩90.2B ) を超えています。長期負債: A038460の短期資産 ( ₩154.2B ) が 長期負債 ( ₩32.0B ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: A038460の 純負債対資本比率 ( 17.4% ) は 満足できる 水準であると考えられます。負債の削減: A038460の負債対資本比率は、過去 5 年間で38.5%から38.3%に減少しました。債務返済能力: A038460の負債は 営業キャッシュフロー によって 十分にカバー されています ( 33.5% )。インタレストカバレッジ: A038460の負債に対する 利息支払い は EBIT ( 10.7 x coverage) によって 十分にカバーされています。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YTech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 11:37終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioSmart Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • Apr 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Aug 01BioSmartLtd (KOSDAQ:038460) Seems To Be Using A Lot Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • May 02Here's Why BioSmartLtd (KOSDAQ:038460) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Mar 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Nov 29These 4 Measures Indicate That BioSmartLtd (KOSDAQ:038460) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩3,735, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 11x in the Tech industry in South Korea. Total returns to shareholders of 17% over the past three years.
お知らせ • Mar 13BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026BioSmart Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,360, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total returns to shareholders of 20% over the past three years.
分析記事 • Feb 02What BioSmart Co.,Ltd.'s (KOSDAQ:038460) 44% Share Price Gain Is Not Telling YouBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have continued their recent momentum with a 44% gain in the last month...
New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩143.6b market cap, or US$99.1m).
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩5,680, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 50% over the past three years.
分析記事 • Dec 15BioSmart Co.,Ltd.'s (KOSDAQ:038460) Shares Climb 44% But Its Business Is Yet to Catch UpBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shares have had a really impressive month, gaining 44% after a shaky period...
New Risk • Dec 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩100.3b market cap, or US$68.5m).
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩3,970, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 11x in the Tech industry in South Korea. Total returns to shareholders of 8.2% over the past three years.
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩74.9b market cap, or US$54.0m).
分析記事 • Apr 23The Market Lifts BioSmart Co.,Ltd. (KOSDAQ:038460) Shares 33% But It Can Do MoreBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders have had their patience rewarded with a 33% share price jump in the...
New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.03% net profit margin). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩102.7b market cap, or US$72.2m).
分析記事 • Apr 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩6.00 (vs ₩915 in FY 2023)Full year 2024 results: EPS: ₩6.00 (down from ₩915 in FY 2023). Revenue: ₩484.3b (up 6.2% from FY 2023). Net income: ₩127.2m (down 99% from FY 2023). Profit margin: 0% (down from 3.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • Mar 12BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025BioSmart Co.,Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 36-16, oncheon-daero 1122beon-gil, chungcheongnam-do, asan South Korea
New Risk • Dec 08New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (₩74.2b market cap, or US$52.1m).
分析記事 • Nov 13BioSmart Co.,Ltd. (KOSDAQ:038460) May Have Run Too Fast Too Soon With Recent 25% Price PlummetThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has fared very poorly over the last month, falling by a substantial...
分析記事 • Oct 14Here's Why We Think BioSmartLtd (KOSDAQ:038460) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩4,205, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩3,810, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 42% over the past three years.
分析記事 • Aug 01BioSmartLtd (KOSDAQ:038460) Seems To Be Using A Lot Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jun 15BioSmart Co.,Ltd. (KOSDAQ:038460) Might Not Be As Mispriced As It Looks After Plunging 26%The BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has softened a substantial 26% over the previous 30 days, handing...
Valuation Update With 7 Day Price Move • Jun 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,530, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 15x in the Tech industry in South Korea. Total loss to shareholders of 32% over the past three years.
お知らせ • Jun 06An unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billionAn unknown buyer agreed to acquire a 13.33% stake in Tc Materials Co., Ltd. from BioSmart Co.,Ltd. (KOSDAQ:A038460) for KRW 10 billion on June 4, 2024. The transaction is expected to close on June 5, 2024.
Valuation Update With 7 Day Price Move • May 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩6,560, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 10x in the Tech industry in South Korea. Total returns to shareholders of 6.0% over the past three years.
分析記事 • May 02Here's Why BioSmartLtd (KOSDAQ:038460) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩4,505, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 11x in the Tech industry in South Korea. Total loss to shareholders of 35% over the past three years.
分析記事 • Apr 11Further Upside For BioSmart Co.,Ltd. (KOSDAQ:038460) Shares Could Introduce Price Risks After 52% BounceThe BioSmart Co.,Ltd. ( KOSDAQ:038460 ) share price has done very well over the last month, posting an excellent gain...
New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (7.0% increase in shares outstanding). Market cap is less than US$100m (₩109.1b market cap, or US$79.8m).
Valuation Update With 7 Day Price Move • Apr 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩4,090, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 31% over the past three years.
分析記事 • Mar 26Shareholders In BioSmartLtd (KOSDAQ:038460) Should Look Beyond Earnings For The Full StoryWe didn't see BioSmart Co.,Ltd.'s ( KOSDAQ:038460 ) stock surge when it reported robust earnings recently. We looked...
Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩915 (vs ₩38.00 in FY 2022)Full year 2023 results: EPS: ₩915 (up from ₩38.00 in FY 2022). Revenue: ₩456.2b (up 16% from FY 2022). Net income: ₩17.9b (up ₩17.2b from FY 2022). Profit margin: 3.9% (up from 0.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jan 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to ₩3,370. The fair value is estimated to be ₩2,795, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Earnings per share has grown by 87%.
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩3,720, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 65% over the past three years.
New Risk • Oct 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (₩72.0b market cap, or US$53.6m).
New Risk • Sep 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Earnings have declined by 31% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Market cap is less than US$100m (₩71.8b market cap, or US$54.2m).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩3,070, the stock trades at a trailing P/E ratio of 54.3x. Average trailing P/E is 12x in the Tech industry in South Korea. Total loss to shareholders of 34% over the past three years.
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩4,515, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 9x in the Tech industry in South Korea. Total loss to shareholders of 9.1% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩3,905, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 10x in the Tech industry in South Korea. Total loss to shareholders of 14% over the past three years.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • Mar 09Is BioSmartLtd (KOSDAQ:038460) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Mar 04New 90-day low: ₩6,140The company is down 19% from its price of ₩7,600 on 04 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 20% over the same period.
分析記事 • Feb 16Returns On Capital At BioSmartLtd (KOSDAQ:038460) Paint An Interesting PictureThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
分析記事 • Jan 29Declining Stock and Decent Financials: Is The Market Wrong About BioSmart Co.,Ltd. (KOSDAQ:038460)?It is hard to get excited after looking at BioSmartLtd's (KOSDAQ:038460) recent performance, when its stock has...
Is New 90 Day High Low • Jan 29New 90-day low: ₩6,230The company is down 37% from its price of ₩9,920 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 48% over the same period.
分析記事 • Jan 11BioSmartLtd (KOSDAQ:038460) Shareholders Have Enjoyed A 51% Share Price GainBioSmart Co.,Ltd. ( KOSDAQ:038460 ) shareholders might be concerned after seeing the share price drop 26% in the last...
Is New 90 Day High Low • Jan 08New 90-day low: ₩7,280The company is down 28% from its price of ₩10,100 on 08 October 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 39% over the same period.
分析記事 • Dec 23BioSmart Co.,Ltd. (KOSDAQ:038460) Looks Interesting, And It's About To Pay A DividendBioSmart Co.,Ltd. ( KOSDAQ:038460 ) is about to trade ex-dividend in the next four days. Ex-dividend means that...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩63.00 Per ShareWill be paid on the 7th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.7% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (1.9%).
分析記事 • Dec 17Does BioSmart Co.,Ltd. (KOSDAQ:038460) Have A Place In Your Dividend Portfolio?Dividend paying stocks like BioSmart Co.,Ltd. ( KOSDAQ:038460 ) tend to be popular with investors, and for good reason...
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩9,670, the stock is trading at a trailing P/E ratio of 58.2x, up from the previous P/E ratio of 45x. This compares to an average P/E of 24x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 110%.
分析記事 • Nov 29These 4 Measures Indicate That BioSmartLtd (KOSDAQ:038460) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Is New 90 Day High Low • Nov 25New 90-day low: ₩8,150The company is down 36% from its price of ₩12,800 on 27 August 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Tech industry, which is up 22% over the same period.
Valuation Update With 7 Day Price Move • Nov 09Market bids up stock over the past weekAfter last week's 20% share price gain to ₩11,650, the stock is trading at a trailing P/E ratio of 11.6x, up from the previous P/E ratio of 9.6x. This compares to an average P/E of 16x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 131%.
Valuation Update With 7 Day Price Move • Oct 27Market bids up stock over the past weekAfter last week's 19% share price gain to ₩10,750, the stock is trading at a trailing P/E ratio of 10.7x, up from the previous P/E ratio of 8.9x. This compares to an average P/E of 20x in the Tech industry in South Korea. Total returns to shareholders over the past three years are 118%.